JAMA
LightNews LightNews
banner
jama.com
JAMA
@jama.com
22K followers 110 following 2.4K posts
JAMA is an international peer-reviewed general medical journal and a member of the JAMA Network family of journals.

🌐 JAMA.com
Posts Replies Media Videos
jama.com
💬 Viewpoint: The Joint Commission and Coalition for Health AI have issued guidance on responsible #AI use in health care, but without a unified evaluation system, US hospitals face liability and efficiency challenges as AI adoption expands.

ja.ma/4ro7Moj
JAMA viewpoint on "New Guidance on Responsible Use of AI" by Sofia Palmieri et al. Published December 3, 2025. Includes summary table of TJC/CHAI guidelines: AI policies, patient privacy, data security, quality monitoring, risk assessment.
December 3, 2025 at 5:15 PM
jama.com
Allergic rhinitis affects about 1 in 6 US adults.

💡 This JAMA Insights summarizes the impact of climate change and air pollution on sinonasal health and discusses evidence-based prevention and management strategies.

ja.ma/4rnralb
A JAMA Insights article titled "Climate Change, Allergic Rhinitis, and Sinusitis," published online December 3, 2025. The article discusses the impact of climate change and air pollution on allergic rhinitis and chronic rhinosinusitis.
December 3, 2025 at 5:00 PM
jama.com
📊 Research Summary: Sacubitril/valsartan lowered NT-proBNP more than enalapril, but did not offer significant advantages in clinical outcomes for patients with HF due to #Chagas disease. Both drugs were tolerated similarly.

ja.ma/3MnYIQ6
JAMA research summary: Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease. Trial results show comparable outcomes between the two drugs, with 922 patients analyzed in Latin America.
December 3, 2025 at 4:45 PM
jama.com
RCT: In patients with #Chagas-related #HFrEF, sacubitril/valsartan did not reduce rates of cardiovascular death or heart failure hospitalization compared with enalapril.

ja.ma/4aex1mK
JAMA study: Sacubitril/valsartan vs. enalapril for heart failure due to Chagas disease. 922 patients randomized. Findings: Sacubitril/valsartan showed a greater reduction in NT-proBNP compared to enalapril. No significant difference in death/hospitalization.
December 3, 2025 at 4:15 PM
jama.com
💬Viewpoint: Eliminating universal hepatitis B birth dose vaccination risks an estimated 8% increase in annual perinatal #HepatitisB infections in the US, increasing preventable chronic disease burden. ja.ma/3Me0zHh
A "JAMA" article, published online December 3, 2025, titled "Universal Hepatitis B Vaccination at Birth—Risks of Revising the Recommendation" by Michael S. Abers et al., discusses ACIP's review and a possible vote to eliminate the birth dose recommendation.
December 3, 2025 at 3:45 PM
jama.com
🩸 Iron deficiency occurs when the body does not have enough stored iron. Worldwide, about 2 billion people have #irondeficiency and 1.2 billion people have iron-deficiency #anemia.

Learn more in this JAMA Patient Page:

ja.ma/3Mr3V9O
An infographic about iron deficiency, its symptoms, and treatment. It mentions fatigue, restless legs, depression, and cravings. Treatments include oral and intravenous iron, the latter for pregnancy, poor absorption, or chronic conditions.
December 3, 2025 at 2:00 PM
jama.com
📊 Research Summary: Individualized high PEEP with recruitment maneuvers did not lower risk of postoperative pulmonary complications vs standard low PEEP in open abdominal surgery.

#CCCF2025

ja.ma/3M42dLw
JAMA Research Summary: Intraoperative Driving Pressure-Guided High PEEP vs Standard Low PEEP for Postoperative Pulmonary Complications. The study included 1435 adults. Postoperative pulmonary complications occurred in 19.8% (high PEEP) vs 17.4% (low PEEP).
December 3, 2025 at 1:15 PM
jama.com
RCT: Intraoperative high PEEP and recruitment maneuvers did not decrease the incidence of postoperative #PulmonaryComplications and were associated with more hypotension during open abdominal surgery.

#CCCF2025

ja.ma/49IOS5k
Infographic from JAMA on PEEP effectiveness during surgery. 750 women and 685 men, adults 18+, median age 66, in 29 hospitals across 5 countries were studied. High PEEP (19.8% outcome) vs Low PEEP (17.4% outcome). Results weren't statistically significant.
December 3, 2025 at 1:10 PM
jama.com
Proactive, risk-stratified intraoperative MAP targets did not improve 6-month disability after elective noncardiac surgery compared with usual care MAP ≥65 mm Hg.

ja.ma/4ilgq2G
JAMA study: Proactive blood pressure management didn't improve post-op disability at 6 months. Population: 1738 women, 1509 men, 59 mean age. Intervention: 3522 patients randomized. Findings: Blood pressure management scored 17.7, usual care 18.2.
December 3, 2025 at 12:00 PM
jama.com
📌 Editor’s Choice from this week's issue of #JAMA:

➡️ eGFR Estimate Variability & Clinical Outcomes,
➡️ #Microplastics and Human Health,
➡️ #Hypotension Management During #Surgery, and more.

ja.ma/4eRp9GH
Cover of JAMA, Journal of the American Medical Association, December 2, 2025 issue. It lists research articles on blood pressure management during surgery, vaccine policy, measles resurgence, and clinical reviews on syphilis and iron deficiency.
December 2, 2025 at 5:30 PM
jama.com
#Microplastics are increasingly detected in human tissues, with potential links to cognitive, cardiovascular, and inflammatory outcomes.

💡 Learn more in this JAMA Insights:
ja.ma/44tEyub
A page from JAMA Insights titled "Microplastics and Human Health," published online October 15, 2025. The article discusses plastics production, microplastics, detection methods, and presence in human tissues.
December 2, 2025 at 5:00 PM
jama.com
Syphilis is an infectious disease caused by Treponema pallidum, a gram-negative spirochete bacterium.

This Review summarizes the epidemiology, diagnosis, treatment, and prevention of #syphilis.

ja.ma/3XWLZX6
A diagram shows two-stage syphilis testing algorithms. The traditional algorithm involves quantitative initial screening and qualitative specific testing. The reverse screening algorithm involves qualitative and quantitative initial screening.
December 2, 2025 at 4:45 PM
jama.com
💬 Editorial: Personalized perioperative blood pressure management did not reduce organ injury or disability compared with standard MAP targets.

ja.ma/48puwM4
A medical paper from JAMA titled 'Perioperative Outcomes—The Limits of Blood Pressure-Centered Strategies' by Matthieu Legrand, François Lamontagne, and Romain Pirracchio. Published online October 12, 2025.
December 2, 2025 at 4:30 PM
jama.com
Individualized perioperative MAP targets did not lower rates of organ injury or death after major abdominal surgery compared with routine blood pressure management at MAP ≥65 mm Hg.

ja.ma/48jpukd
JAMA study: Individualized perioperative blood pressure management based on preoperative nighttime mean arterial pressure did not improve outcomes. Population: 747 men, 387 women. Intervention: 571 in each group. Findings: 33.5% vs 30.5%.
December 2, 2025 at 4:15 PM
jama.com
Systemic amyloidosis from transthyretin (ATTR) protein is the most common type of amyloidosis that causes cardiomyopathy. Approximately 50 000 to 150 000 people in the US have heart failure due to ATTR amyloidosis.

💾 Save this Review for your bibliography:
ja.ma/44wLuGY
A diagram from JAMA showing cardiac amyloidosis due to transthyretin protein. It details TTR monomers, misfolded amyloidgenic monomers, and amyloid fibrils, along with amyloid infiltration in the heart, leading to ventricular wall thickening and potential heart conditions.
December 2, 2025 at 3:00 PM
jama.com
The neurodegenerative brain disease #CTE, caused by repeated blows to the head, can only be determined by evidence of tau buildup after death.

But new research reveals brain changes before tau appears—and the potential for earlier detection and intervention ja.ma/4inDJJ6
Young Athletes With Repeated Head Blows May Have Brain Changes
This Medical News article discusses new research identifying cellular changes in the brains of younger athletes with repeated head impacts, which may provide an early warning for development of chronic traumatic encephalopathy.
ja.ma
December 2, 2025 at 2:00 PM
jama.com
Will 2026 be the year of real-world evidence that #AI can actually improve patient care? JAMA+ AI Editor in Chief Roy Perlis and Associate Editor Yulin Hswen discuss in this special episode marking 1 year since the launch of JAMA+ AI. ja.ma/43PXSSq
What Will 2026 Bring for AI in Health?
In this special episode marking 1 year since the launch of JAMA+ AI, the JAMA Network’s channel for all things artificial intelligence (AI) in health, JAMA Associate Editor Yulin Hswen and I reflect on what 2026 might bring. The generative models have thinking and deep research modes and they’re...
ja.ma
December 2, 2025 at 1:00 PM
jama.com
Yesterday, @who.int published a guideline in JAMA on the use and indications of #GLP-1 therapies for the management of #obesity in adults. The guideline offers two conditional recommendations to inform clinical practice and health policy.

Read the guideline: ja.ma/48hMMa2
JAMA: World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. Published online December 1, 2025. Discusses obesity as a chronic disease and the role of GLP-1 therapies.
December 2, 2025 at 12:00 PM
jama.com
💬 Viewpoint: Combination-only approvals for new #HIV drugs limit generic substitution and sustain high antiretroviral prices, even after key patents expire.

#WorldAIDSDay2025

ja.ma/4pwRTKi
A page from JAMA (Journal of the American Medical Association) titled "Combination-Only Approvals as a Barrier to Affordable HIV Care" by S. Sean Tu et al. It discusses prescription drug costs and HIV treatment access.
December 1, 2025 at 5:15 PM
jama.com
💬 Viewpoint: The proposed federal budget and legislative actions, including the One Big Beautiful Bill Act, threaten health care coverage and prevention programs for patients with #HIV, with over 40% relying on #Medicaid for access.

ja.ma/49DMGMl
An article from JAMA titled "World AIDS Day—At a Crossroads" by Anna K. Person, MD; Colleen F. Kelley, MD, MPH. Published online December 1, 2025. The article discusses progress, threats, and the future of HIV prevention.
December 1, 2025 at 5:00 PM
jama.com
💬 Editorial: The LEVOECMO RCT found no benefit of levosimendan in increasing the rate of successful VA-ECMO weaning or improving mortality compared with placebo; risk of ventricular arrhythmias was greater with levosimendan.

ja.ma/4pwSnA6
A page from JAMA, published online December 1, 2025, titled "Levosimendan and Weaning From VA-ECMO" by Mark H. Drazner, MD, MSc. It discusses VA-ECMO's use in cardiogenic shock and the LEVOECMO trial in France.
December 1, 2025 at 4:45 PM
jama.com
📊 Research Summary: Early treatment with levosimendan was not associated with improved timing of ECMO weaning, lower mortality, or shorter ICU stay for adults with severe cardiogenic shock supported by #VAECMO.

ja.ma/4reZNtA
Research summary: Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock. The study analyzes VA-ECMO weaning with levosimendan vs. placebo, finding no significant difference in outcomes.
December 1, 2025 at 4:30 PM
jama.com
RCT: Among patients with severe but potentially reversible cardiogenic shock, early administration of levosimendan did not significantly shorten time to successful venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning.

ja.ma/3KsaNTV
Infographic from JAMA on ECMO weaning. It compares levosimendan to placebo. 205 patients were randomized. Levosimendan and placebo had 68.3% weaning success. Concludes levosimendan did not improve ECMO weaning.
December 1, 2025 at 4:15 PM
jama.com
Today, @who.int published a guideline in JAMA on the use and indications of #GLP-1 therapies for the management of #obesity in adults.

Explore the new guideline: ja.ma/48lTvQe
Join WHO for a public, live-streamed webinar at 10 AM ET: ja.ma/3MpjFtX
JAMA publishes, on December 1, 2025, the 'World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults,' highlighting obesity's impact and the role of GLP-1 therapies.
December 1, 2025 at 3:00 PM
jama.com
💬 Viewpoint: Mandatory chromosomal screening in women’s sport lacks scientific justification and risks harm, echoing legacy policies abandoned over 2 decades ago.

ja.ma/4p7hEBk
JAMA article: 'The Return to Genetic Testing in Women's Sport—Repeating History Without Evidence' by Tam Tran, Sammer Marzouk, Minh Huu Nhat Le, and Nguyen Tien Huy, published online October 15, 2025.
December 1, 2025 at 2:00 PM